Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 5/20 | 0.47 |
| ▸ | HSP90AA1 | P07900 | 4/20 | 0.46 |
| ▸ | HSP90AB1 | P08238 | 4/20 | 0.46 |
| ▸ | TNFRSF1A | P19438 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | RBP4 | P02753 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4598135 | 0.83 | HSP90AA1 (0.52) | KCNH2HSP90AA1HSP90AB1GAAALDH1A1 | |
| SCHEMBL8605250 | 0.78 | PKM (0.61) | KCNH2HSP90AA1HSP90AB1TNFRSF1AGAA | |
| SCHEMBL4462385 | 0.78 | KCNH2 (0.49) | KCNH2HSP90AA1HSP90AB1GAAPDK2 | |
| SCHEMBL4462380 | 0.78 | ALDH1A1 (0.50) | KCNH2HSP90AA1HSP90AB1GAAPOLB | |
| SCHEMBL5634575 | 0.77 | KCNH2 (0.54) | KCNH2HSP90AA1HSP90AB1GAARBP4 | |
| SCHEMBL4599086 | 0.76 | MEN1 (0.42) | HSP90AA1HSP90AB1ALDH1A1RBP4PDK2 | |
| SCHEMBL19317241 | 0.73 | HSP90AA1 (0.52) | HSP90AA1HSP90AB1ALDH1A1RBP4L3MBTL1 | |
| SCHEMBL4597476 | 0.72 | PTGS2 (0.59) | — | |
| SCHEMBL3637333 | 0.72 | TNFRSF1A (0.56) | TNFRSF1A | |
| SCHEMBL2772941 | 0.72 | TNFRSF1A (0.53) | KCNH2TNFRSF1APOLBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1727793-B1 | SUBSTITUTED AZETIDINE COMPOUNDS AS CYCLOOXYGENASE-1 - CYCLOOXYGENASE-2 INHIBITORS, AND THEIR PREPARATION AND USE AS MEDICAMENTS | ESTEVE LABOR DR (ES) | 2008-04-09 | — | — | EP | claimed |
| US-7232812-B2 | Substituted azetidine compounds, their preparation and use as medicaments | LABORATORIOS DE DR. ESTEVE S.A. (ES) | 2007-06-19 | — | — | US | claimed |
| US-20070093469-A1 | Substituted azetidine compounds as cyclooxygenase-1-cyclooxygenase-2 inhibitors, and their preparation and use as medicaments | LABORATORIOS DEL DR. ESTEVE S.A (ES) | 2007-04-26 | — | — | US | claimed |
| EP-1727793-A1 | SUBSTITUTED AZETIDINE COMPOUNDS AS CYCLOOXYGENASE-1 - CYCLOOXYGENASE-2 INHIBITORS, AND THEIR PREPARATION AND USE AS MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2006-12-06 | — | — | EP | claimed |
| WO-2005077896-A1 | SUBSTITUTED AZETIDINE COMPOUNDS AS CYCLOOXYGENASE-1-CYCLOOXYGENASE-2 INHIBITORS, AND THEIR PREPARATION AND USE AS MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2005-08-25 | — | — | WO | claimed |
| US-20050182041-A1 | Substituted Azetidine compounds, their preparation and use as medicaments | LABORATOIOS DE DR. ESTEVE S.A. (ES) | 2005-08-18 | — | — | US | claimed |
| EP-1727793-B1 | SUBSTITUTED AZETIDINE COMPOUNDS AS CYCLOOXYGENASE-1 - CYCLOOXYGENASE-2 INHIBITORS, AND THEIR PREPARATION AND USE AS MEDICAMENTS | ESTEVE LABOR DR (ES) | 2008-04-09 | — | — | EP | disclosed |
| US-7232812-B2 | Substituted azetidine compounds, their preparation and use as medicaments | LABORATORIOS DE DR. ESTEVE S.A. (ES) | 2007-06-19 | — | — | US | disclosed |
| US-20070093469-A1 | Substituted azetidine compounds as cyclooxygenase-1-cyclooxygenase-2 inhibitors, and their preparation and use as medicaments | LABORATORIOS DEL DR. ESTEVE S.A (ES) | 2007-04-26 | — | — | US | disclosed |
| EP-1727793-A1 | SUBSTITUTED AZETIDINE COMPOUNDS AS CYCLOOXYGENASE-1 - CYCLOOXYGENASE-2 INHIBITORS, AND THEIR PREPARATION AND USE AS MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2006-12-06 | — | — | EP | disclosed |
| WO-2005077896-A1 | SUBSTITUTED AZETIDINE COMPOUNDS AS CYCLOOXYGENASE-1-CYCLOOXYGENASE-2 INHIBITORS, AND THEIR PREPARATION AND USE AS MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2005-08-25 | — | — | WO | disclosed |
| US-20050182041-A1 | Substituted Azetidine compounds, their preparation and use as medicaments | LABORATOIOS DE DR. ESTEVE S.A. (ES) | 2005-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093469-A1 | Substituted azetidine compounds as cyclooxygenase-1-cyclooxygenase-2 inhibitors, and their preparation and use as medicaments | PTGS1, PTGS2, PTGES2 | KCNH2 2552/4885HSP90AA1 482/4885HSP90AB1 644/4885 |
| US-20050182041-A1 | Substituted Azetidine compounds, their preparation and use as medicaments | AZI2, NISCH, QDPR | KCNH2 617/4885HSP90AA1 1727/4885HSP90AB1 1982/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.